Compare Tango Therapeutics Inc. (TNGX) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Weibo Corp — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Weibo Corp trades at $6.43 (market cap $1.61B). The key difference: Tango Therapeutics Inc. is far larger — about 2.3× Weibo Corp's market cap, and Weibo Corp pays a 9.3% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Weibo Corp for 103 Days on average.
| TNGX | WB | |
|---|---|---|
Market Cap | $3.75B | $1.61B |
Volume | 9,619,106 | 585,008 |
Sector | Health | Media |
52-Week High | $32.90 | $11.52 |
52-Week Low | $7.50 | $6.33 |
Typical Hold Time | 0 Days | 103 Days |
Enterprise Value | $2.77B | $841.53M |
Dividend Yield | — | 9.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Weibo (WB) trades at $6.51, down 0.53% with bearish technical signals despite attractive valuation metrics including a P/E of 5.42 and P/B of 0.4. The company reported Q2 2026 EPS of $0.38, beating expectations, but faces declining user metrics and advertising revenue challenges. Cash flow trends show volatility with a significant net outflow in 2024 followed by recovery in 2025.
WB presents as a deep-value opportunity with strong profitability margins but faces growth headwinds from user engagement declines and competitive pressures. Analyst sentiment is mixed with 41% buy ratings versus 45% hold, reflecting uncertainty about the company's ability to maintain relevance in China's social media landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
